ResMed Inc. Unveils Stewardship Presentation Highlighting Fiscal 2025 Achievements and 2030 Strategy

Reuters
09/13
ResMed Inc. Unveils Stewardship Presentation Highlighting Fiscal 2025 Achievements and 2030 <a href="https://laohu8.com/S/MSTR">Strategy</a>

ResMed Inc. recently shared highlights from its fiscal 2025 performance, focusing on its strategy for 2030. The company reported a revenue of $5.1 billion with an operating margin of 33% GAAP and 34% Non-GAAP. ResMed serves over 140 countries and employs more than 10,000 people. Their revenue by business is divided among Devices, Masks & Other, and Residential Care Software $(RCS)$, while regional revenue is primarily from the U.S., Canada, and Latin America. The company's focus areas include enhancing patient experience through innovative solutions for Sleep Apnea, improving outcomes for COPD patients, and providing residential care software solutions. ResMed aims to empower 500 million lives by 2030 and has already impacted over 154 million lives with its digital health products and cloud-based software solutions in the past year. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ResMed Inc. published the original content used to generate this news brief on September 12, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10